2nd World-RNA Based Therapeutics & Vaccines Summit South Korea
South Korea’s mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in clinical-stage vaccines. Also, with the growing momentum of ARPA-H initiatives focused on personalized mRNA cancer therapies and strong government backing continues to drive the development of safer, more effective RNA-based medicines.
Amid this innovation, the World RNA-Based Therapeutics & Vaccines Summit returns to South Korea for its second year, highlighting breakthroughs in mRNA design, therapeutic pipelines, targeted delivery, and solutions to key manufacturing and analytical challenges. This is your chance to de-risk your program strategies, unlock insights from international leaders, and forge networks to develop better RNA medicines for patients faster.
As Korean RNA and vaccine companies strive to establish partnerships, out-license their assets, or create co-development collaborations with global companies, join 80+ mRNA therapeutic and vaccine developers to differentiate your technology and learn how to generate meaningful data to open up the possibilities of future partnerships.
View the full event guide here.
Across three days you can expect to learn how to:
- Pioneer circular RNA engineering platforms to discover, synthesize and optimize efficacious therapies for patients faster
- Optimize antigen selection & cost-effective manufacturing processes to accelerate mRNA-based cancer vaccine development
- Leverage RNA technology to achieve clinical progress for in vivo CAR and gene editing therapies
- Unleash novel LNP formulations to exploit the full potential of non-viral delivery vehicles
With content for multiple teams, you can take advantage of the group discounts of up to 20% available.
